

Tab 6

From: Chinery, Bob
Sent: Tuesday, January 07, 2003 12:51 PM
To: Suz Redfearn
Subject: RE: CHANGE OF INTERVIEW TIME

Hi Suz,

Here are answers to these questions. Unfortunately I have another interview(in person) at two o'clock today. Therefore I could answer any follow-up questions via e-mail after 4:00pm or by phone at 3:30 provided my other interview is completed by then.

Let me know of anything else we can do to help.

Regards,

Bob Chinery

-----Original Message-----

From: Suz Redfearn [SMTP:suzredfearn@starpower.net]
Sent: Tuesday, January 07, 2003 9:27 AM
To: Tvnews2003@aol.com
Subject: Re: CHANGE OF INTERVIEW TIME

Ok, here are a few questions:

How has your company reacted to the swirl of controversy over ephedra?
Cytodyne has focused heavily on product testing as a way of reassuring consumers that our ephedra based Xenadrine-RFA-1 product is completely safe when used as directed. Since the controversy began a couple of years ago, we've sponsored a series of additional independent scientific studies at leading research centers and major universities. In all instances, subjects achieved significant weight-loss effects without any serious adverse events. Now, with over seven separate independent studies behind it, Xenadrine is clearly one of the most tested and proven dietary supplements on the market today. In addition to this product specific testing, there have been over fifty-five other independent clinical studies performed on ephedra or ephedrine and all have supported its safety. In total, this amounts to far more testing than what is done with most of the prescription drugs sold today.

How long had you had Ephedra-based products on the market? How were sales? Have you pulled them? If so, why?
Our ephedra product, Xenadrine-RFA-1, has been on the market since 1997 and has consistently grown in sales every year since its introduction. It is clear that word of mouth from the millions of satisfied users who've lost weight safely has contributed to this steady growth. As a result of its consumption patterns (estimated 20 million consumers per year just in the U.S) and the bedrock of clinical research behind it, Cytodyne firmly believes that ephedra has earned its place on the market as a safe and effective tool for weight-loss.

As you see it, what are you competitors doing in response to the ephedra controversy? Has this caused a massive shift? How?

All ephedra products are not the same. Some have higher dosages of ephedra and more servings throughout the day. Others are combined with additional ingredients which have not been thoroughly tested. It appears that the competitors that have not subjected their products to the appropriate clinical testing are the ones that are pulling their ephedra products. The competitors that are intent on weathering the storm of controversy appear to be the responsible ones which have proven the safety and efficacy of their products through solid scientific research. This is obviously a great thing for consumers as it will help weed out the not so good products.

What sort of products are they replacing their ephedra-based supplements with? What do you think of "bitter orange"?

After two years of intense research and development, Cytodyne has recently launched a new non-ephedra product called Xenadrine-EFX. The original objective of our researchers was not necessarily to develop an ephedrine-free version of Xenadrine but to develop the next generation of diet supplements, in other words, create a product that would be even more effective at boosting metabolism and promoting weight-loss. This objective appears to have been reached when the EFX formula was put to the test directly in a clinical trial against two leading ephedra based diet supplements. The results of that study even surprised the researchers when the non-ephedra EFX formula far outperformed both ephedra products at increasing metabolism and resulting caloric expenditure. The new Xenadrine-EFX product has been on the market since April of 2002 and has already far surpassed sales of the ephedra based Xenadrine. We believe this explosive popularity is the result of its extraordinary efficacy. This phenomenal consumer response to the new product opens the possibility that the new formula may ultimately eliminate the need for the original version. Cytodyne will continue to closely monitor consumer feedback before it finalizes any decision like that.

Regarding green tea, when was the study on it published in the Journal of the American College of Nutrition? What sorts of studies have been done on its safety? How long were those studies ongoing? How is its effects on the body different from ephedra's effects? How long has your company been selling it?

The most recent green tea extract/caffeine based product comparative study was completed on the new Xenadrine-EFX product. This study was presented at the annual 2002 American College of Nutrition meeting and published in the October issue of the Journal of American College of Nutrition.

Green Tea is the second most consumed beverage worldwide. As an extract, it has been safely taken and used in a wide variety of settings. From the green tea cancer studies (where it has been found to lower the incidence of esophageal and stomach cancers) to its metabolic enhancement effects, scientists worldwide have been testing products like and including Xenadrine-EFX for their health enhancing effects. Being that tea has been used for over 5000 years and product specific research is mounting, the popularity will only grow, because the safety is already established.

Green tea extract, by itself, has been found to enhance the metabolic rate by positively affecting the sympathetic nervous system. Dr. Abdul Dullo published an excellent and well-detailed study in the American Journal of Clinical Nutrition detailing the safety and efficacy of green tea extract combined with caffeine. That seminal paper postulated and positioned this product to be an effective alternative to ephedra by itself. Two studies by Drs. Krieger and Schwartz at Miami Research Associates have found similar results as Dr. Dulloo. A third study which is pending publication has also found that the Xenadrine-EFX product had no untoward effects when compared with exercise. The study found that there were no negative effects on the heart, blood pressure, sleep quality and important quality of life issues such as that.

What other changes are likely in the industry as a result of all this? The major change we hope to see is that more companies will invest the time and money into thoroughly researching their products before bringing them to market.

Thanks!

-- Suz

----- Original Message -----

From: Tvnews2003@aol.com <mailto:Tvnews2003@aol.com>

To: suzredfearn@starpower.net <mailto:suzredfearn@starpower.net>

Cc: bobc@prosourceonline.com <mailto:bobc@prosourceonline.com>;

kellyc@prosourceonline.com <mailto:kellyc@prosourceonline.com>

Sent: Monday, January 06, 2003 6:05 PM

Subject: CHANGE OF INTERVIEW TIME

Bob Chinery has requested his interview occur at 11AM Tomorrow.